CSIMarket
 
Renalytix Plc  (RNLX)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $0.2071 $0.01 5.663%
Day's High: $0.225 Week Perf: -2.77 %
Day's Low: $ 0.19 30 Day Perf: -30.81 %
Volume (M): 934 52 Wk High: $ 0.94
Volume (M$): $ 194 52 Wk Avg: $0.45
Open: $0.21 52 Wk Low: $0.18



 Market Capitalization (Millions $) 22
 Shares Outstanding (Millions) 106
 Employees 52
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -28
 Cash Flow (TTM) (Millions $) -13
 Capital Exp. (TTM) (Millions $) 0

Renalytix Plc
Renalytix Plc is a healthcare diagnostics company that specializes in developing and commercializing clinical diagnostic solutions for kidney disease. The company's main focus is on developing AI-driven predictive analytics and clinical decision support tools for kidney disease management. Renalytix aims to improve the identification and monitoring of patients at risk of kidney disease and provide personalized care plans to optimize patient outcomes. The company collaborates with leading academic institutions and healthcare providers to develop and validate its diagnostic solutions. Renalytix is headquartered in London, UK.


   Company Address: 2 Leman Street London 0
   Company Phone Number: 3139 2910   Stock Exchange / Ticker: RNLX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ADMT        4.5% 
DBGI   -11.6%    
DVA        1.58% 
• View Complete Report
   



Stock Market Announcement

Renalytix plc Lists on OTCQB to Enhance U.S. Market Presence and Advance Kidney Disease Management Initiatives,

Published Tue, Oct 8 2024 11:00 AM UTC

Renalytix plc Expands U.S. Presence with OTCQB Listing, Accelerating Developments in Kidney Disease ManagementRenalytix plc, a leader in the field of AI-driven diagnostics aimed at improving kidney health, announced the commencement of trading of its American Depository Shares (ADSs) on the OTCQB Venture Market under the symbol RNLXY. Effective from market open on October 8,...

Product Service News

Renalytix and Steno Diabetes Center Partner to Pave the Way for Precision Medicine in Diabetes-Related Kidney Disease...

Published Thu, Jul 11 2024 11:00 AM UTC

Renalytix plc, a renowned artificial intelligence-enabled in vitro diagnostics company, has joined forces with the Steno Diabetes Center (Steno) in Copenhagen, marking an unprecedented expansion of their KidneyIntelX platform beyond the United States. With the unwavering goal of optimizing clinical management of kidney disease, enhancing patient outcomes, and advancing value...

Product Service News

Medicare Approves Groundbreaking KidneyIntelX.dkd Test A New Era in Chronic Kidney Disease Management Begin...

Published Fri, Jun 14 2024 11:00 AM UTC

Medicare Approves Coverage for KidneyIntelX.dkd: Significant Milestone for Chronic Kidney Disease ManagementIn a groundbreaking development aimed at revolutionizing chronic kidney disease (CKD) management, Medicare has issued a final coverage determination for KidneyIntelX.dkd, a pioneering diagnostic test designed by Renalytix to predict the risk of CKD progression. This d...

Financing Agreement

Renalytix Raises $4 Million in Financing to Propel Global Disease Care Innovation

Published Mon, Apr 8 2024 11:01 AM UTC



In a major development, Renalytix plc, a leading medical technology firm redefining critical global diseases care, has announced a registered direct offering of ordinary shares. The offering, priced at $0.75 per NASDAQ ADS ($0.375 per common stock share), seeks to raise a total financing amount of up to $4 million. The company has secured DB Capital Partners Health...

Management Announcement

Revolutionizing Kidney Disease Management: KidneyIntelX Recognized in Final KDIGO 2024 Clinical Guideline

Published Thu, Mar 14 2024 11:01 AM UTC



Chronic Kidney Disease (CKD) affects millions of people worldwide and imposes a significant burden on healthcare systems globally. As we enter a new era of personalized medicine, risk prediction and tailored treatment plans are crucial in managing this complex and widespread condition. The inclusion of KidneyIntelX in the Final KDIGO 2024 Clinical Guideline for CKD...







Renalytix Plc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com